Document 0766
 DOCN  M9610766
 TI    Progress in anti-HIV structure-based drug design.
 DT    9601
 AU    Gait MJ; Karn J; MRC Laboratory of Molecular Biology, Cambridge, UK.
 SO    Trends Biotechnol. 1995 Oct;13(10):430-8. Unique Identifier : AIDSLINE
       MED/96030281
 AB    The course of drug development for the treatment of HIV-1 infection and
       AIDS is being revolutionized by high-resolution structures of essential
       viral proteins. We survey the impact on drug design of the recently
       elucidated structural knowledge of two essential enzymes, reverse
       transcriptase and protease, and three new targets, the viral integrase
       and the gene regulatory protein-RNA interactions, Tat-TAR and Rev-RRE.
 DE    Antiviral Agents/*PHARMACOLOGY  *Drug Design  Drug Resistance  DNA
       Nucleotidyltransferases/ANTAGONISTS & INHIB  Human  HIV/*DRUG
       EFFECTS/GENETICS  HIV Protease Inhibitors/PHARMACOLOGY  Reverse
       Transcriptase Inhibitors/PHARMACOLOGY  Virus Replication/DRUG EFFECTS
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).